42nd first announcement 03 10 2011
-
Upload
gene-banawa -
Category
Documents
-
view
224 -
download
0
Transcript of 42nd first announcement 03 10 2011
-
8/7/2019 42nd first announcement 03 10 2011
1/7
PHILIPPINE HEART ASSOCIATION
1108, 11th Floor East Tower, PSE Centre
Exchange Road, Ortigas Center, Pasig City
Tel. No.: (+632) 470.5525
Fax No.: (+632) 687.7797
E-mail: [email protected]@philheart.org
Website: www.philheart.org
-
8/7/2019 42nd first announcement 03 10 2011
2/7
1
MESSAGE
EUGENE B. REYES, MDChair, Scientific Committee
SATURNINO P. JAVIER, MDChair, Organizing Committee
ELEANOR A. LOPEZ, MDPresident
Every year, the field of Cardiology grows by leaps and
bounds. As knowledge in the discipline accumulates, clinical
applicability and practice patterns are guided throughformulation of guidelines, consensus statements and
recommendations from international and local associations,
experts groups and key opinion leaders. These are quite
essential if standards are to be set for management, research
and training purposes.
Heretofore, validated goals and outcome expectations
dictate on the direct ions we take, the strategies we employ and
the options we choose. Yet, such standards or goals become
meaningless and inappropriate if they are not tempered with
the realities we confront everyday legislation, socio-economic
restrictions, accessibility, unavailability of drug and technology,
among others.
A compleat clinician integrates all these into a cohesive
body of approaches and policies. This annual convention seeks
to focus on all these and more. Welcome and we wish you allan intellectually rewarding scientific activity.
ELEANOR A. LOPEZ, MD
ISABELO V. ONGTENGCO JR., MD
ROMEO B. CRUZANDRE S. KAHN
SATURNINO P. JAVIER, MD
EUGENE B. REYES, MD
JOEL M. ABANILLA, MD
TIMOTHY C. DY, MD
MA. CONSOLACION DOLOR-TORRES, MD
MARIA TERESA B. ABOLA, MD
President
Vice President
VP for FinanceVP for External Affairs
Secretary
Treasurer
Director
Director
Director
Immediate Past President
42nd ANNUAL PHA CONVENTION
ORGANIZING COMMITTEE
SATURNINO P. JAVIER, MD
EUGENE B. REYES, MD
JOEL M. ABANILLA, MD
ISABELO V. ONGTENGCO JR., MD
TIMOTHY C. DY, MD
MA. CONSOLACION DOLOR-TORRES, MD
MARIA TERESA B. ABOLA, MD
PEDRO P. SAN DIEGO JR., MD
ERLYN C. DEMERRE, MD
Over-all Chair
Chair, Scientific Committee
Chair, Sessions Committee
Chair, Registration
Chair, Exhibits & Physical Arrangement
Chair, Socials
Chair, Protocol
Chair, Information Technology
Chair, Publication
OFFICERS 2010-2011
-
8/7/2019 42nd first announcement 03 10 2011
3/7
-
8/7/2019 42nd first announcement 03 10 2011
4/7
-
8/7/2019 42nd first announcement 03 10 2011
5/7
-
8/7/2019 42nd first announcement 03 10 2011
6/7
ABSTRACTABSTRACT PREPARATION INSTRUCTION
1. The abstract must be submitted on the enclosed Abstract Form.
2. The abstract must be contained in the space provided and use a type size no
smaller than 10 point.
3. Type title in Bold using upper and lower case letters and not to exceed 200
words.4. Type complete names of authors (M.D. or other principal degrees not
necessary). List responsible institutions and their respective cities and
provinces
5. Leave a blank line after author(s)/institution(s) and before abstract text.
6. Abstract text should include purpose, methods, results, and conclusions. Do
not include references or credits. Simple tables or graphs may be included if
they fit within the space allowed.
7. Use standard abbreviations. Place special or unusual abbreviations in
parentheses after the full word the first time it appears. A limit of fiveadditional special abbreviations may be used in each abstract.
8. Please avoid printing on lines of abstract box.
9. Deadline for submission of abstracts: on or before March 15, 2011 and the
final manuscripts on or before March 31, 2011
10. Accepted oral abstracts will be presented during a special session the exact
date of which will be announced at a later date. Posters will be presented
during a special poster presentation session and during breaks in the exhibit
hall.
11. Abstract accepted for presentation will be published in the April to June Issue
of the Philippine Journal of Cardiology.
12. Submit the original abstract (unfolded) by first class or overnight mail to:
Philippine Heart Association Secretariat
1108, 11th Floor East Tower, PSE Centre
Exchange Road, Ortigas Center, Pasig City
13. The complete manuscript should be in a Compact Disc (CD) or Digital
Versatile Disc(DVD) and one (1) hardcopy using MS-Word Application.
Author should provide, and identify as , 5-8 keywords or short phrases that
will assist a reseacher in identifying an information material.
14. Indicate the required information on the authors as follows:
NAME OF AUTHOR/S
NAME OF PRESENTOR
INSTITUTION
TEL NO. FAX NO. E-MAIL ADDRESS
98
-
8/7/2019 42nd first announcement 03 10 2011
7/7
FAMILY NAME GIVEN NAME MIDDLE NAME
INSTITUTION/COMPANY
ADDRESS ZIPCODE
TELEPHONE No. FAX No. E-MAIL ADDRESS
PRC No. PMA No.
REGISTRATION FEE
Please check:
ADVANCE REGULAR DAILY
(Until March 30, 2011) (After March 30, 2011)
PHA member* P 1,200 1,500 700**
Non-member 1,400 1,700 700**
Resident 1,000 1,200 700**
Fellow-in-Training 1,000 1,200 700**
Medical Student 1,000 1,200 700**
Nurse/Technician 1,000 1,200 700**
PHA family member 600 700 700**
Exhibitor 600 800 700**
* Annual membership fee is not included in registration fee**Daily registration fee does not include convention kit.
Signature of Registrant Date
11
REGISTRATION FORMABSTRACT CONTENTS
CAPITALIZE ENTIRE ABSTRACT TITLE
Author. Underline only presenting authors name.Institution, City
OBJECTIVES: State main question or study objective(s) or
hypothesis.
DESIGN: Describe study design. Indicate if randomized, blinded
and if temporal direction, retrospective or prospective.
SETTING: Indicate the study setting (hospital, clinic, community).
Also include the level of cl inical care (primary or tertiary); privatepractice or institutional.
PATIENTS/PARTICIPANTS: State selection procedures, entry
criteria and numbers of participants entering and finishing the
study.
INTERVENTIONS, IF ANY: Describe the essential features of an
intervention/exposure, including the method and duration ofadministration.
MAIN OUTCOME MEASURE(S): The primary study outcome
measure should be indicated as planned before the data collection
began.
RESULTS: Describe measurements that are not evident from the
nature of the main results and indicate any blinding. If possible,the results should be accompanied by confidence intervals (most
often the 95% interval) and the exact level of statistical
significance. For comparative studies, confidence intervals should
relate to the differences between groups. Absolute values should
be indicated when risk changes or effect sizes are given.
CONCLUSIONS: State only those conclusions of the study that are
directly supported by data, along with their clinical application
(avoiding generalization) or whether additional study is required
before the information should be used in usual clinical settings.
10